Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

pET30a-SARS-CoV2-ORF3b (S23Q)
(Plasmid #165088)

Ordering

Item Catalog # Description Quantity Price (USD)
Plasmid 165088 Standard format: Plasmid sent in bacteria as agar stab 1 $75 *

* Login to view industry pricing.

Backbone

Growth in Bacteria

  • Bacterial Resistance(s)
    Kanamycin, 50 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    Low Copy

Gene/Insert

  • Gene/Insert name
    Severe acute respiratory syndrome coronavirus 2 ORF3b (S23Q)
  • Species
    SARS-CoV2
  • Mutation
    Stop codon to glutamine at 23rd amino acid

Cloning Information

  • Cloning method Ligation Independent Cloning

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pET30a-SARS-CoV2-ORF3b (S23Q) was a gift from Rick Tarleton (Addgene plasmid # 165088 ; http://n2t.net/addgene:165088 ; RRID:Addgene_165088)
  • For your References section:

    A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses. Shen H, Forgacs D, Chapla D, Moremen KW, Wells L, Hamer SA, Tompkins SM, Ross TM, Rouphael N, Edupuganti S, Collins MH, Tarleton RL.. medRxiv 2021.(pre-print) 01.20.21249279 10.1101/2021.01.20.21249279